Daridorexant + Placebo
ApprovedCompleted 0 watching 0 views this week๐ฅ Hot
80
Development Stage
โ
Pre-clinicalโ
Phase 1โ
Phase 2โ
Phase 35
ApprovedIndication / Disease
Insomnia Disorder
Conditions
Insomnia Disorder, Nocturia
Trial Timeline
Feb 16, 2023 โ Apr 18, 2024
NCT ID
NCT05597020About Daridorexant + Placebo
Daridorexant + Placebo is a approved stage product being developed by Idorsia for Insomnia Disorder. The current trial status is completed. This product is registered under clinical trial identifier NCT05597020. Target conditions include Insomnia Disorder, Nocturia.
Hype Score Breakdown
Clinical
30
Activity
20
Company
5
Novelty
10
Community
12
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05597020 | Approved | Completed |
| NCT05458193 | Phase 1 | Completed |
Competing Products
20 competing products in Insomnia Disorder